Page 2 - Tim Clackson News Today

/PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the...

The company is conducting a clinical trial of a pan-variant inhibitor for KIT-mutant GIST and hopes to advance an EGFR pan-variant inhibitor to the clinic soon.

/PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the...

/PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer...

/PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer...

/PRNewswire/ -- Theseus Pharmaceuticals, Inc. ("Theseus"), a biopharmaceutical company focused on improving the lives of cancer patients through the discovery,...

/PRNewswire/ -- Theseus Pharmaceuticals, a biotechnology company shaping the future of targeted oncology by developing best-in-class, pan-variant kinase...

Share this article CAMBRIDGE, Mass., May 4, 2021 /PRNewswire/ --  Theseus Pharmaceuticals, a biotechnology company shaping the future of targeted oncology by developing best-in-class, pan-variant kinase inhibitors, today announced the appointment of Tim Clackson, Ph.D., as Chief Executive Officer and as a member of the Companys Board of Directors. He succeeds interim CEO Iain Dukes, D.Phil., Theseus Co-Founder and OrbiMed Venture Partner, who will serve as Theseus Executive Chairman. "I am thr...